According to BioPharma Dive, Pfizer has signed a collaboration deal worth up to $2.6 billion to develop ‘in vivo’ CAR-T therapies aimed at treating autoimmune conditions. The deal involves a Chinese partner and marks Pfizer’s entry into a new area of cell therapy.
This development matters to pharma and biotech executives as it signals a major investment in next-generation therapies that could change treatment options for autoimmune diseases. The move may also affect competitive positioning and future partnership strategies in the sector.